IBRX270319C00018000
IBRX Mar 19 2027 18.00 Call
optionOPRA
InactiveOct 9, 2026
1.20USD+20.000%(+0.20)50Vol59OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
18
Expiration
Mar 19, 2027
DTE
150d
Moneyness
OTM
Intrinsic
$0.00
IBRX 18 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | — | — | 0 | 0 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | — | — | 0 | 0 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | $0.30 | +0.00% | 20 | 20 |
| Jan 15, 2027 | 87d | $0.20 | -67.74% | 3 | 28 |
| Mar 19, 2027 | 150d | $1.20 | +20.00% | 50 | 59 |
| Apr 16, 2027 | 178d | — | — | 0 | 0 |
| May 21, 2027 | 213d | $2.05 | +127.78% | 1 | 20 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.